These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23207070)

  • 1. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.
    Gonzaga IM; Soares-Lima SC; de Santos PT; Blanco TC; de Reis BS; Quintella DC; de Oliveira IM; de Faria PA; Kruel CD; Andreollo NA; de Simão TA; Pinto LF
    BMC Cancer; 2012 Dec; 12():569. PubMed ID: 23207070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
    Shigaki H; Baba Y; Watanabe M; Miyake K; Murata A; Iwagami S; Ishimoto T; Iwatsuki M; Yoshida N; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S485-91. PubMed ID: 23274581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
    Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
    BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma.
    Liu QW; Fu JH; Luo KJ; Yang HX; Wang JY; Hu Y; Yang H; Bella E
    Dis Esophagus; 2011 Jul; 24(5):374-80. PubMed ID: 21615826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
    Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
    Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.
    Abedi-Ardekani B; Dar NA; Mir MM; Zargar SA; Lone MM; Martel-Planche G; Villar S; Mounawar M; Saidi F; Malekzadeh R; Hainaut P
    BMC Cancer; 2012 Dec; 12():602. PubMed ID: 23244191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.
    García-Inclán C; López F; Pérez-Escuredo J; Cuesta-Albalad MP; Vivanco B; Centeno I; Balbín M; Suárez C; Llorente JL; Hermsen MA
    Cell Oncol (Dordr); 2012 Dec; 35(6):443-50. PubMed ID: 23055340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma.
    Gou HF; Li X; Qiu M; Cheng K; Li LH; Dong H; Chen Y; Tang Y; Gao F; Zhao F; Men HT; Ge J; Su JM; Xu F; Bi F; Gao JJ; Liu JY
    PLoS One; 2013; 8(4):e62175. PubMed ID: 23637996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.
    Kato H; Arao T; Matsumoto K; Fujita Y; Kimura H; Hayashi H; Nishiki K; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Yasuda T; Okuno K; Shiozaki H; Nishio K
    Int J Oncol; 2013 Apr; 42(4):1151-8. PubMed ID: 23426935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues.
    Zhang G; Zhang Q; Zhang Q; Yin L; Li S; Cheng K; Zhang Y; Xu H; Wu W
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):587-94. PubMed ID: 19823871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
    Dias-Santagata D; Lam Q; Bergethon K; Baker GM; Iafrate AJ; Rakheja D; Hoang MP
    Mod Pathol; 2011 Jul; 24(7):974-82. PubMed ID: 21423156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
    Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
    Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang.
    Zhang L; Wang Y; Bai G; Zhang J; Yang M; Ma X
    Tumour Biol; 2015 Dec; 36(12):9277-83. PubMed ID: 26099724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
    Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
    Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
    Petty RD; Dahle-Smith A; Stevenson DAJ; Osborne A; Massie D; Clark C; Murray GI; Dutton SJ; Roberts C; Chong IY; Mansoor W; Thompson J; Harrison M; Chatterjee A; Falk SJ; Elyan S; Garcia-Alonso A; Fyfe DW; Wadsley J; Chau I; Ferry DR; Miedzybrodzka Z
    J Clin Oncol; 2017 Jul; 35(20):2279-2287. PubMed ID: 28537764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
    Villalva C; Duranton-Tanneur V; Guilloteau K; Burel-Vandenbos F; Wager M; Doyen J; Levillain PM; Fontaine D; Blons H; Pedeutour F; Karayan-Tapon L
    Cancer Med; 2013 Jun; 2(3):296-304. PubMed ID: 23930206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.
    Sato-Kuwabara Y; Neves JI; Fregnani JH; Sallum RA; Soares FA
    BMC Cancer; 2009 Jan; 9():6. PubMed ID: 19128465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.
    Secq V; Villeret J; Fina F; Carmassi M; Carcopino X; Garcia S; Metellus I; Boubli L; Iovanna J; Charpin C
    Br J Cancer; 2014 Feb; 110(4):1045-52. PubMed ID: 24423920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.